Champions Oncology (NASDAQ:CSBR – Get Free Report) and 10x Genomics (NASDAQ:TXG – Get Free Report) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, profitability, analyst recommendations, institutional ownership and valuation.
Insider & Institutional Ownership
41.3% of Champions Oncology shares are held by institutional investors. Comparatively, 84.7% of 10x Genomics shares are held by institutional investors. 46.3% of Champions Oncology shares are held by insiders. Comparatively, 8.8% of 10x Genomics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Profitability
This table compares Champions Oncology and 10x Genomics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Champions Oncology | -1.82% | -25.77% | -3.71% |
| 10x Genomics | -10.84% | -8.26% | -6.52% |
Analyst Ratings
This is a breakdown of current recommendations and price targets for Champions Oncology and 10x Genomics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Champions Oncology | 1 | 0 | 0 | 0 | 1.00 |
| 10x Genomics | 1 | 12 | 5 | 0 | 2.22 |
10x Genomics has a consensus price target of $65.40, suggesting a potential upside of 3.09%. Given 10x Genomics’ stronger consensus rating and higher possible upside, analysts plainly believe 10x Genomics is more favorable than Champions Oncology.
Earnings & Valuation
This table compares Champions Oncology and 10x Genomics”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Champions Oncology | $60.66 million | 1.12 | -$1.17 million | ($0.08) | -60.94 |
| 10x Genomics | $616.91 million | 13.40 | -$43.54 million | ($0.52) | -122.00 |
Champions Oncology has higher earnings, but lower revenue than 10x Genomics. 10x Genomics is trading at a lower price-to-earnings ratio than Champions Oncology, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
Champions Oncology has a beta of 0.48, suggesting that its share price is 52% less volatile than the S&P 500. Comparatively, 10x Genomics has a beta of 2.03, suggesting that its share price is 103% more volatile than the S&P 500.
Summary
10x Genomics beats Champions Oncology on 8 of the 14 factors compared between the two stocks.
About Champions Oncology
Champions Oncology, Inc. engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. It uses its technology to offer solutions to Translational Oncology Solutions, which includes pharmaceutical and biotechnology companies; and Personalized Oncology, which assists physicians in developing personalized treatment options for their cancer patients. The company was founded by James M. Martell and David Sidransky on June 4, 1985 and is headquartered in Hackensack, NJ.
About 10x Genomics
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity and networks on a cell-by-cell basis; single cell gene expression flex; single cell immune profiling used to study the immune system; single cell Assay for Transposase Accessible Chromati (ATAC) solution to understand the epigenetic state; and single cell multiome ATAC + gene expression which enables simultaneous interrogation of both the RNA and chromatin accessibility, using ATAC in a single cell. The company also provides Visium platform which enables researchers to understand the spatial positions of biological analytes within tissues at high resolution; and Xenium platform for in situ analysis. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
Receive News & Ratings for Champions Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Champions Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
